Ritlecitinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Ritlecitinib comprises 3 peer-reviewed publications across 3 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Alopecia Areata. Most recent publication: Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata., Dermatol Ther (Heidelb), 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.
    Saadeddin A, Purohit V, Huh Y, et al. · AAPS J · 2024
    PubMed: PMID 38267790 · NCT05128058
  2. Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
    King B, McMichael A, Sinclair R, et al. · Dermatol Ther (Heidelb) · 2025
    PubMed: PMID 41083802 · NCT06873945 (ALLEGRO-100) · Alopecia Areata
  3. A Phase 1, Open-Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6-12 Years With Alopecia Areata.
    Gonzalez ME, Browning J, Smith S, et al. · Pediatr Dermatol · 2025
    PubMed: PMID 39924925 · NCT05650333 · Alopecia Areata

Publications by year

2024–2025: 3 publications.

2024
1
2025
2

Publications by indication

Alopecia Areata (2)

  • Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
    Dermatol Ther (Heidelb) · 2025 · PMID 41083802 · NCT06873945
  • A Phase 1, Open-Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6-12 Years With Alopecia Areata.
    Pediatr Dermatol · 2025 · PMID 39924925 · NCT05650333

Publications by journal

  • AAPS J1 paper
  • Dermatol Ther (Heidelb)1 paper
  • Pediatr Dermatol1 paper

All Ritlecitinib publications (3)

2025 (2 papers)

  1. Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
    King B, McMichael A, Sinclair R, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 41083802 · NCT06873945 (ALLEGRO-100) · Alopecia Areata
  2. A Phase 1, Open-Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6-12 Years With Alopecia Areata.
    Gonzalez ME, Browning J, Smith S, et al. · Pediatr Dermatol · 2025 · Derived
    PubMed: PMID 39924925 · NCT05650333 · Alopecia Areata

2024 (1 paper)

  1. Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.
    Saadeddin A, Purohit V, Huh Y, et al. · AAPS J · 2024 · Derived
    PubMed: PMID 38267790 · NCT05128058

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Thu, 14 May 2026 22:01:34 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).